Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Retisert Clear all
Recruiting Phase 4 Interventional

Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study

NCT04207931
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions
Topical steroid class I-II, Triamcinolone Acetonide, Doxycyline, Minoxidil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 21, 2026, 12:10 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema

NCT00490815
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 21, 2026, 12:10 AM EDT
Terminated Phase 2 Interventional Results available

Sorafenib-induced Hand- Foot Skin Reaction Treatment

NCT00667589
View directory record Official record
Conditions
Hand-foot Skin Reaction, Rash
Interventions
urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream, bland emollient cream (Udderly smooth® Udder Cream)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 21, 2026, 12:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant

NCT03145025
View directory record Official record
Conditions
Uveitis, Posterior
Interventions
Retisert, Fluocinolone Acetonide Intravitreal Implant
Device · Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 21, 2026, 12:10 AM EDT
Withdrawn Phase 4 Interventional

Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study

NCT02902744
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
ILUVIEN®
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 21, 2026, 12:10 AM EDT
Completed Phase 1 Interventional

Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis

NCT01781936
View directory record Official record
Conditions
Uveitis Affecting the Posterior Segment
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Glenn Jaffe
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 21, 2026, 12:10 AM EDT
Completed Phase 3 Interventional Results available

Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study

NCT01304706
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Alpharetta, Georgia
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 21, 2026, 12:10 AM EDT
Terminated Phase 2 Interventional Results available

Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy

NCT00695318
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
55 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 29, 2015 · Synced Oct 21, 2026, 12:10 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Using an Internet Study to Improve Adherence for Psoriasis Patients

NCT01802580
View directory record Official record
Conditions
Psoriasis
Interventions
Internet Survey, fluocinonide 0.05% ointment
Behavioral · Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 21, 2026, 12:10 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants

NCT00407082
View directory record Official record
Conditions
Noninfectious Posterior Uveitis
Interventions
fluocinolone acetonide intravitreal implant, Fluocinolone acetonide 2.1mg
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
6 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Oct 21, 2026, 12:10 AM EDT
Terminated Phase 4 Interventional Results available

Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma

NCT00669071
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%, Cetaphil® Moisturizing Cream as Inactive Control
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 74 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
La Jolla, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 21, 2026, 12:10 AM EDT
Completed Phase 3 Interventional

The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment

NCT05486468
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
Interventions
Yutiq 0.18 MG Drug Implant, Sham Injection
Drug · Other
Lead sponsor
Texas Retina Associates
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 12:10 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

NCT01694186
View directory record Official record
Conditions
Non-Infectious Uveitis
Interventions
FAI insert, Sham injection
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
16
States / cities
Beverly Hills, California • Sacramento, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 21, 2026, 12:10 AM EDT
Completed Not applicable Interventional

Retisert and Cataract Surgery in Patients With Severe Uveitis

NCT00570830
View directory record Official record
Conditions
Intermediate Uveitis, Posterior Uveitis
Interventions
Retisert (fluocinolone acetonide implant)
Device
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 21, 2026, 12:10 AM EDT
Not listed Phase 2 Interventional

A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration

NCT00032396
View directory record Official record
Conditions
Macular Degeneration
Interventions
Retisert Implant
Drug
Lead sponsor
Control Delivery Systems
Industry
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2006 · Synced Oct 21, 2026, 12:10 AM EDT
Completed Early Phase 1 Interventional

Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO)

NCT00636493
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
fluocinolone acetonide (Retisert Implant)
Device
Lead sponsor
Glenn Jaffe
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Oct 21, 2026, 12:10 AM EDT
Not listed Phase 4 Interventional

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

NCT05322070
View directory record Official record
Conditions
Uveitis, Posterior
Interventions
Fluocinolone Acetonide Intravitreal Implant 0.18 mg
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Fullerton, California • Glendale, California • Pasadena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 21, 2026, 12:10 AM EDT
Completed Phase 1 Interventional

Prophylactic Anecortave Acetate in Patients With a Retisert Implant

NCT00570479
View directory record Official record
Conditions
Uveitis, Posterior, Glaucoma
Interventions
anecortave acetate
Drug
Lead sponsor
Texas Retina Associates
Other
Eligibility
10 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 21, 2026, 12:10 AM EDT
Completed Phase 2 Interventional Results available

Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy

NCT01422408
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Fluocinonide Cream, Management of Therapy Complications, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 21, 2026, 12:10 AM EDT
Completed No phase listed Observational

Cutaneous Lupus Medication Experience Study

NCT02176148
View directory record Official record
Conditions
Cutaneous Lupus
Interventions
fluocinonide 0.05% cream
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 21, 2026, 12:10 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT02260986
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 21, 2026, 12:10 AM EDT
Completed Phase 4 Interventional Results available

Multicenter Uveitis Steroid Treatment (MUST) Trial

NCT00132691
View directory record Official record
Conditions
Uveitis
Interventions
fluocinolone acetonide intraocular implant, oral corticosteroid with immunosuppressive agents as needed
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
13 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 21, 2026, 12:10 AM EDT
Completed Phase 3 Interventional Results available

Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis

NCT02748512
View directory record Official record
Conditions
Non-Infectious Uveitis
Interventions
FAI Insert administered using the Mk II inserter, FAI Insert administered using the Mk I inserter
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Colorado Springs, Colorado • Waltham, Massachusetts • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 21, 2026, 12:10 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, Upadacitinib, Topical corticosteroids (TCS)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
59
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 21, 2026, 12:10 AM EDT